• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Top 5 Most-Read Regulatory Articles of 2024

December 25th 2024

By Skylar Jeremias

Article

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.

Top 5 Most-Read Oncology Articles of 2024

December 24th 2024

By Skylar Jeremias

Article

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.

BioRationality: A Critical Analysis of Pfizer Views on Sustainability of Biosimilars

December 23rd 2024

By Sarfaraz K. Niazi, PhD

Article

Top 5 Most-Read Legal Articles of 2024

December 23rd 2024

By Skylar Jeremias

Article

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and addressing challenges like litigation, regulatory hurdles, and patent disputes that shape the competitive landscape of affordable biologics.

Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access

December 22nd 2024

By Skylar Jeremias

Article

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.

The Top 5 Most-Read Gastroenterology Articles of 2024

December 21st 2024

By Skylar Jeremias

Article

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the year, while FDA and European approvals for ustekinumab biosimilars are set to improve access and reduce costs for patients with Crohn disease and ulcerative colitis.

The Top 5 Biosimilar Articles for the Week of December 16

December 20th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 16, 2024.

China's Biosimilar Market: Trastuzumab Uptake and Future Trends

December 19th 2024

By Cameron Santoro

Article

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing market share and reducing costs despite initial barriers.

FDA Approves Steqeyma: The Seventh Stelara Biosimilar

December 18th 2024

By Skylar Jeremias

Article

The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025.

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

December 18th 2024

By Skylar Jeremias

Article

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.